Profile data is unavailable for this security.
Mergers & acquisitions
Acquired company | LLY:NYQ since announced | Transaction value |
---|---|---|
Mablink Bioscience SAS | 42.46% | -- |
POINT Biopharma Global Inc | 63.19% | 1.38bn |
Versanis Bio Inc | 102.08% | 1.93bn |
Emergence Therapeutics AG | 91.51% | 8.33m |
Sigilon Therapeutics Inc | 91.51% | 316.64m |
Data delayed at least 15 minutes, as of Jun 15 2024 00:00 BST.
Holder | Shares | % Held |
---|---|---|
Caixa DTVM SAas of 29 Feb 2024 | 424.45k | 0.00% |
Western Asset Management Company DTVM Ltda.as of 29 Feb 2024 | 200.28k | 0.00% |
Safra Asset Management Ltda.as of 29 Feb 2024 | 59.00k | 0.00% |
Bram Bradesco Asset Management S/A DTVMas of 29 Feb 2024 | 48.73k | 0.00% |
Warren Brasil Gest�o e Administra��o e Recursos Ltda.as of 29 Feb 2024 | 9.63k | 0.00% |
XP Allocation Asset Management Ltda.as of 29 Feb 2024 | 971.00 | 0.00% |
BTG Pactual WM Gest�o de Recursos Ltda.as of 29 Feb 2024 | 137.00 | 0.00% |
More ▼
Data from 29 Feb 2024 - 06 Jun 2024Source: FactSet Research Systems Inc.